



#10 11/24/00
TBray

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:	
November 10, 2000 Date	 Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING
ANTIBODIES TO
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Helms, L.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection herewith. Even if an Official Action had issued in the last few days, no fee would still be due to formally enter the listed documents into the record in light of the following certification.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that the first three items of information contained in this Supplemental Information Disclosure Statement were cited in a communication from the patent office in a counterpart international application not more than three months prior to the filing of the present statement, as evidenced by the date of the enclosed search report (October 04, 2000). The listed co-pending application is the U.S. counterpart to the PCT application in which the disclosed communication was issued. The Official Filing Receipt confirming the Serial No. for the co-pending application was only mailed from the PTO on September 11, 2000, less than three months before the filing of the present statement.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.00282.

Respectfully submitted,



Shelley D.M. Fussey
Reg. No. 39,458
Agent for Applicant

WILLIAMS, MORGAN & AMERSON, P.C.
7676 Hillmont, Suite 250
Houston, Texas, 77040
(713) 934-4079
Date: November 10, 2000